Form 4: Organovo Holdings Executive Chairman Keith Murphy Reports Stock and Option Transactions

Keith Murphy, Executive Chairman of Organovo Holdings, reports acquisition of restricted stock units and options.

Summary

• On August 7, 2024, Keith Murphy, the Executive Chairman of Organovo Holdings, filed a Form 4.
• The filing reports the acquisition of 19,607 shares of common stock represented by restricted stock units.
• These restricted stock units will vest on the earlier of August 7, 2025, or the date of the 2025 annual meeting, subject to acceleration upon a change of control.
• Murphy also acquired options to purchase 574,923 shares of common stock at an exercise price of $0.5368 on August 5, 2024.
• These options vest in three equal annual installments starting August 5, 2025.
• Additionally, Murphy acquired options to purchase 143,731 shares of common stock at an exercise price of $0.5368 on August 5, 2024.
• These options become exercisable if the 90-trading day average closing sales price of Organovo's common stock reaches at least $1.53.
• Following these transactions, Murphy directly owns 132,641 shares of common stock, 574,923 options, and 143,731 options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock and option transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of stock and options by the Executive Chairman could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedules for the restricted stock units and options provide a timeline for potential future equity ownership changes.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules and performance-based conditions (like the $1.53 stock price hurdle) are also standard features of these grants.

Stakeholder Impact

• The transactions reported in the Form 4 could influence investor sentiment and potentially impact the company's stock price.

Key Dates

Keywords

Organovo Holdings, Keith Murphy, Form 4, Executive Chairman, Stock Options, Restricted Stock Units, Beneficial Ownership, ONVO